# Elephas Biosciences

Source: https://onco.cc/companies/elephas-biosciences/  
OnCo record `elephas-biosciences` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Elephas keeps thin slices of a patient's tumour biopsy alive in the laboratory and measures how they react to immunotherapy drugs, to help predict whether a treatment is likely to work before it is given.

## Summary

Elephas Biosciences develops elive, a live-tissue platform that prepares standard core-needle biopsies with an automated cutting instrument and gel, keeps the tissue alive, and measures changes in cytokine response after exposure to immunotherapies ex vivo. The company describes it as tumour-agnostic and sells it in three ways: the elive Test, which it says is available to select oncologists through an early access programme; services and platform components for pharmaceutical research and development; and research tools. Its site carries a 'For Research Use Only, not for use in diagnostic procedures' statement. It runs observational studies to measure how well elive predicts response to immune checkpoint inhibitors across solid tumours, including ELEPHAS-01 in non-small-cell lung cancer (NCT05478538), the ELEPHAS-02 basket study (NCT05520099), ELEPHAS-05 (NCT07327489) and a Mayo Clinic-sponsored study (NCT06349642). Its news page lists commercial partnerships with Neuberg Diagnostics in India and Invitrocue in Southeast Asia, and a peer-reviewed paper in Cell Reports Medicine.

## Fields

- Kind: Company
- Last checked: 2026-11-04
- Also known as: Elephas; Elephas Biosciences Corporation
- HQ: Madison, WI
- Type: diagnostics
- Website: https://elephas.com/

## Notes

- Founding year not stated on the pages read; omitted.
- Its trials span many tumour types (bladder, colorectal, endometrial, head and neck, kidney, liver, melanoma, NSCLC, TNBC and others), so no cancers are linked to the company.
- None of its four trials (NCT05478538, NCT05520099, NCT07327489, NCT06349642) is an OnCo trial record yet. NCT06349642 is sponsored by Mayo Clinic with Elephas as collaborator.

## Sources

- Official website: https://elephas.com/
- About Elephas: https://elephas.com/about-us
- Clinical trials page: https://elephas.com/resources/clinical-trials
- News: https://elephas.com/news
- ClinicalTrials.gov NCT07327489 (ELEPHAS-05): https://clinicaltrials.gov/study/NCT07327489
- ARCH Venture Partners portfolio entry (archived 16 Oct 2026): https://web.archive.org/web/20261016142320/https://www.archventure.com/portfolio/

## Connected records

- fronts: [Diagnostics & Biomarkers](https://onco.cc/fronts/diagnostics/), [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- technologies: [Functional (ex vivo) drug testing](https://onco.cc/technologies/functional-drug-testing/)
- companies: [ARCH Venture Partners](https://onco.cc/companies/arch-venture-partners/)

---
JSON: https://onco.cc/api/v1/entities/elephas-biosciences.json